These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16305595)

  • 21. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder.
    Drutz HP; Appell RA; Gleason D; Klimberg I; Radomski S
    Int Urogynecol J Pelvic Floor Dysfunct; 1999; 10(5):283-9. PubMed ID: 10543335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of anticholinergic drugs on attention span and short-term memory skills in children.
    Giramonti KM; Kogan BA; Halpern LF
    Neurourol Urodyn; 2008; 27(4):315-8. PubMed ID: 17828786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "Unblinding" in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident.
    DuBeau CE; Khullar V; Versi E
    Neurourol Urodyn; 2005; 24(1):13-20. PubMed ID: 15570576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Overactive bladder. New anticholinergic drug controls urinary urge].
    MMW Fortschr Med; 2004 Jul; 146(27-28):51. PubMed ID: 15526670
    [No Abstract]   [Full Text] [Related]  

  • 25. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder.
    Lee JG; Hong JY; Choo MS; Kwon HY; Chung DY; Lee KS; Lee JY; Lee T
    Int J Urol; 2002 May; 9(5):247-52. PubMed ID: 12060436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study.
    Burger M
    Eur Urol; 2007 Nov; 52(5):1516-7. PubMed ID: 17574732
    [No Abstract]   [Full Text] [Related]  

  • 27. [Detrusitol and memory impairment].
    Jansson A; Eliasson E
    Lakartidningen; 2007 Feb 14-20; 104(7):515. PubMed ID: 17375683
    [No Abstract]   [Full Text] [Related]  

  • 28. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
    Jonas U; Rackley RR
    Eur Urol; 2006 Jan; 49(1):187-8; author reply 188-90. PubMed ID: 16310930
    [No Abstract]   [Full Text] [Related]  

  • 29. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Olshansky B; Serra DB
    Clin Pharmacol Ther; 2008 Feb; 83(2):231-2; author reply 233. PubMed ID: 18043690
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Syndrome of inappropriate antidiuretic hormone associated with tolterodine therapy.
    Bryan MK; Nguyen MT; Hilas O
    Consult Pharm; 2010 May; 25(5):320-2. PubMed ID: 20497930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative adherence to oxybutynin or tolterodine among older patients.
    Gomes T; Juurlink DN; Mamdani MM
    Eur J Clin Pharmacol; 2012 Jan; 68(1):97-9. PubMed ID: 21710237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Urinary incontinence--treatment].
    Hader C; Welz-Barth A; Keller T
    Dtsch Med Wochenschr; 2003 Apr; 128(14):750-2. PubMed ID: 12673531
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P; Kaplan S; De Koning Gans HJ; Millard R
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.
    Reinberg Y; Crocker J; Wolpert J; Vandersteen D
    J Urol; 2003 Jan; 169(1):317-9. PubMed ID: 12478180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Schaefer W
    J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.
    Todorova A; Vonderheid-Guth B; Dimpfel W
    J Clin Pharmacol; 2001 Jun; 41(6):636-44. PubMed ID: 11402632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.
    Diefenbach K; Jaeger K; Wollny A; Penzel T; Fietze I; Roots I
    Sleep Med; 2008 Jul; 9(5):579-82. PubMed ID: 17921051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of tolterodine in children after oxybutynin failure.
    Bolduc S; Upadhyay J; Payton J; Bägli DJ; McLorie GA; Khoury AE; Farhat W
    BJU Int; 2003 Mar; 91(4):398-401. PubMed ID: 12603422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolterodine-induced hyponatraemia.
    Juss JK; Radhamma AK; Forsyth DR
    Age Ageing; 2005 Sep; 34(5):524-5. PubMed ID: 16107463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.